Summary:
Do you or a loved one suffer from memory loss, mild cognitive impairment due to Alzheimer’s disease or mild dementia?
Medication not relieving your symptoms? Are you looking for new options?
If so, they may qualify for a clinical research study for people who have mild cognitive impairment symptoms due to Alzheimer’s disease or mild dementia. The purpose of the study is to evaluate the efficacy and safety of investigational RenewTM NCP-5 therapy for mild cognitive impairment due to Alzheimer’s disease or Mild Dementia.
What is RenewTM NCP-5 Therapy?
RenewTM NCP-5 Therapy is a non-surgical device that has been FDA-cleared to enhance blood flow and may improve quality of life.
Benefits of RenewTM NCP-5 Therapy:
Improved blood circulation:
Good blood circulation is the cornerstone of good health. Blood delivers nutrients and oxygen and removes waste from our cells. When blood flows freely and efficiently, the body is able to defend itself against disease. Poor circulation flow can result in serious health problems such as heart disease, diabetes, stroke, high blood pressure, dementia, and cancer.
To be eligible for this study, participants must:
- Be experiencing mild to moderate memory loss
- Be 55-85 years of age
- Be on stable medications for past 30 days and plan to remain on stable medications
Those who qualify for this study may be compensated for their time and travel.
Free transportation available.